Doxycycline: a first-line treatment for bullous pemphigoid?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

1. Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology.Antibiotics (Basel, Switzerland) · 2022
   Article
2. Bullous Pemphigoid in a Patient with Longstanding Hailey-Hailey Disease Complicated by Eczema Herpeticum: Managing the Coexistence of Three Different Blistering Conditions.The Journal of clinical and aesthetic dermatology · 2020
   Article
3. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.Frontiers in immunology · 2018
   Article
4. BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.Frontiers in immunology · 2017
   Review
5. Bullous pemphigoid.Anais brasileiros de dermatologia
   Review

Corrections and comments

• Comment on
  Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.2017

Authors and funding

3 authors at 3 institutions in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as